Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
Retrieved on:
Tuesday, October 10, 2023
Pressure, Diagnosis, Hospital, Physician, NYSE, TSX, Acquisition, FFR, Model Business Corporation Act, Piper, Fractional flow reserve, EBITDA, PCI, HVS Global Hospitality Services, TAVR, DLA, DPR, Workflow, Credit agreements in South Africa, DLA Piper, CAD, Growth, Goldman Sachs, Vascular closure device, GAAP, Patient, Coronary artery disease, Pharmaceutical industry, Medical imaging, Fine chemical, Bank, Haemonetics
BOSTON, Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.
Key Points:
- OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications.
- Stewart Strong, President, Global Hospital at Haemonetics, said, "With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification.
- Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x.
- Haemonetics posted supplemental slides with additional information about this transaction to Haemonetics' investor relations website.